Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals' stock is experiencing a decline following a downgrade by Leerink Partners from Outperform to Market Perform, along with a reduced price target from $60 to $56.
September 27, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agios Pharmaceuticals' stock is trading lower due to a downgrade by Leerink Partners from Outperform to Market Perform, and a price target cut from $60 to $56.
The downgrade from Leerink Partners is significant as it changes the stock's rating from Outperform to Market Perform, indicating a less favorable outlook. Additionally, the price target reduction suggests a lower expected valuation, contributing to the stock's decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100